Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059 ; volume:63 ; number:7 ; day:22 ; month:6 ; year:2024 ; pages:981-997 ; date:7.2024
Clinical pharmacokinetics ; 63, Heft 7 (22.6.2024), 981-997, 7.2024

Creator
Wu, Jen-Hao
Pennesi, Edoardo
Bautista, Francisco
Garrett, May
Fukuhara, Kei
Brivio, Erica
Ammerlaan, Anneke C. J.
Locatelli, Franco
Sluis, Inge M. van der
Rossig, Claudia
Chen-Santel, Christiane
Bielorai, Bella
Petit, Arnaud
Starý, Jan
Díaz-de-Heredia, Cristina
Rives, Susana
O’Marcaigh, Aengus
Rizzari, Carmelo
Engstler, Gernot
Nysom, Karsten
Rubio-San-Simón, Alba
Bruno, Benedicte
Bertrand, Yves
Brethon, Benoît
Rialland, Fanny
Plat, Geneviève
Dirksen, Uta
Sramkova, Lucie
Zwaan, C. Michel
Huitema, Alwin D. R.
Contributor
SpringerLink (Online service)

DOI
10.1007/s40262-024-01386-z
URN
urn:nbn:de:101:1-2410062108095.248357007640
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:21 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Wu, Jen-Hao
  • Pennesi, Edoardo
  • Bautista, Francisco
  • Garrett, May
  • Fukuhara, Kei
  • Brivio, Erica
  • Ammerlaan, Anneke C. J.
  • Locatelli, Franco
  • Sluis, Inge M. van der
  • Rossig, Claudia
  • Chen-Santel, Christiane
  • Bielorai, Bella
  • Petit, Arnaud
  • Starý, Jan
  • Díaz-de-Heredia, Cristina
  • Rives, Susana
  • O’Marcaigh, Aengus
  • Rizzari, Carmelo
  • Engstler, Gernot
  • Nysom, Karsten
  • Rubio-San-Simón, Alba
  • Bruno, Benedicte
  • Bertrand, Yves
  • Brethon, Benoît
  • Rialland, Fanny
  • Plat, Geneviève
  • Dirksen, Uta
  • Sramkova, Lucie
  • Zwaan, C. Michel
  • Huitema, Alwin D. R.
  • SpringerLink (Online service)

Other Objects (12)

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia

Relapsed Acute Lymphoblastic Leukemia

Relapsed Acute Lymphoblastic Leukemia

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors

Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies

Related objects